Pfizer beats 3Q net forecasts on lower charges, higher sales
Pfizer is reporting third-quarter profit of $2.84 billion, topping expectations.
AstraZeneca wins US approval for lymphoma drug
U.S. regulators have approved a new treatment for people with a rare form of non-Hodgkin lymphoma.
Aetna weighs short-term plans as Trump administration pushes the policies
NEW YORK (Reuters) - Aetna Inc. (NYSE:AET) Chief Executive Mark Bertolini said during a conference call on Tuesday that the company is considering re-launching a pre-Affordable Care Act product is had for transition insurance of less than one year.
People ‘don’t know where to go’ for opioid treatment, A&E’s ‘Dope Man’ says
Tim Ryan, author of “From Dope to Hope,” on the opioid crisis in America.
Hospital exec accused of lewd acts toward college students
An executive with New Jersey's largest private health care system is accused of performing lewd acts in front of female University of Delaware students.
Aetna beats profit estimates on lower Obamacare losses
Aetna Inc. cut losses in its Obamacare business in the third quarter, helping the U.S. health insurer post a higher-than-expected profit and raise its full-year earnings forecast.
Aetna beats profit estimates on lower Obamacare losses
Aetna Inc cut losses in its Obamacare business in the third quarter, helping the U.S. health insurer post a higher-than-expected profit and raise its full-year earnings forecast.
Google-bred Waymo aims to shift robotic cars into next gear
Google's self-driving car spin-off is accelerating efforts to convince the public that its technology is almost ready to safely transport people without any human assistance at all.
Merck and Cooper Tire stumble; CalAtlantic leaps
Stocks that moved substantially or traded heavily Monday: Advanced Accelerator Applications SA, up $7.59 to $80.50
Markets Right Now: Stocks closing lower as drugmakers fall
The latest on developments in financial markets (All times local): 10 a.m.
Opioid billionaire INSYS founder resigns from board, ‘confident’ he will be vindicated from bribery charges
INSYS Therapeutics’ (NASDAQ:INSY) founder Dr. John N. Kapoor resigned from his role with the company’s board in the wake of being charged with participating in a nationwide opioid bribery and kickback scheme.
Novartis to buy France's Advanced Accelerator for $3.9b
Swiss drugmaker Novartis on Monday offered to buy France's Advanced Accelerator Applications in a $3.9 billion cash deal to strengthen the oncology portfolio at the world's biggest maker of prescription medicines.
Japan transport officials probe faulty Subaru inspections
Officials of Japan's ministry of land and transport conducted on-site checks Monday at two factories of the automaker Subaru where unqualified workers were inspecting its cars, as reports said the company plans to recall 255,000 vehicles to be re-inspected.
GM settles California suit over alleged defects concealment
General Motors has agreed to a $13.9 million settlement with Orange County, California, after prosecutors accused the auto giant of concealing serious safety defects to avoid costly recalls and part replacements.
3 reasons why CVS would want to buy health insurer Aetna
A CVS-Aetna combination could create a health colossus that can reach deeper into the average customer's life to manage care and cut costs, according to analysts who follow the companies.
Tech giants lead rally as stocks near records; Amazon surges
Technology companies are jumping Friday morning as investors applaud third-quarter reports from big names including Microsoft, Intel, and Alphabet, Google's parent company.
Recalls this week: infant motion seats, baby gyms
More than 60,000 infant motion seats are being recalled because the motor can overheat, posing a fire hazard.
Merck swings to 3Q loss on big charge but raises forecast
Merck & Co. is reporting a third-quarter loss of $56 million after a profit in the same period a year earlier, but it still beat Wall Street expectations.
Merck tops profit estimates on Keytruda sales
Merck & Co on Friday reported a quarterly profit that beat analysts' estimates, benefiting from sales of its immuno-oncology drug Keytruda.
Subaru chief says inspections were flawed, like Nissan's
Japanese automaker Subaru is investigating whether it carried out illegal inspections on its own vehicles and if any recalls might be needed.













